Literature DB >> 2191805

Livedo reticularis.

A B Fleischer1, S D Resnick.   

Abstract

A wide variety of internal diseases may be associated with livedo reticularis. In adults, the most frequently encountered associated diseases are characterized by vessel wall disease or intravascular obstruction. In the former group, lupus erythematosus is particularly important, since LR along with anticardiolipin antibodies appears to be a marker of serious cerebrovascular and renal disease. Appropriate evaluation of patients presenting with LR includes a careful history and physical examination. Laboratory studies, including a complete blood count, platelets, coagulation profile, cryoproteins, antinuclear antibodies, and anticardiolipin antibodies, are useful screening tools for the important associated diseases. Table 1 summarizes the spectrum of entities associated with LR and points up the challenge of evaluating this distinctive cutaneous finding.

Entities:  

Mesh:

Year:  1990        PMID: 2191805

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  5 in total

1.  Livedo reticularis and related disorders.

Authors:  Steven M Dean
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-04

Review 2.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

3.  Reticulate dermatoses.

Authors:  Keshavmurthy A Adya; Arun C Inamadar; Aparna Palit
Journal:  Indian J Dermatol       Date:  2014-01       Impact factor: 1.494

4.  Amantadine-induced livedo reticularis--Case report.

Authors:  Maria Victória Quaresma; Ana Carolina Dias Gomes; Aline Serruya; Dâmia Leal Vendramini; Lara Braga; Alice Mota Buçard
Journal:  An Bras Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.896

5.  Cutaneous metastasis of urothelial carcinoma resulting in vascular occlusion and livedo racemosa.

Authors:  Anita S Savell; Bryn Morris; Michael R Heaphy
Journal:  JAAD Case Rep       Date:  2020-04-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.